In January 2002, Atrix received United States Food and Drug Administration approval for Eligard
Atrix's marketing partner for the Eligard
product line, anticipates this new therapy will be an important addition in the fight against prostate cancer.
This new patent is specific to the composition of our proprietary Atrigel drug delivery system with leuprolide acetate, the active component in our Eligard
prostate cancer products.
For complete ELIGARD
prescribing information, please go to: http://tolmar.
The company's biggest contributor to revenue growth during 2002-2006 was product sales of Visudyne and Eligard
In addition, the brand of LHRH agonist (Lupron [Abbott Laboratories, Saint Laurent,QC], Zoladex [AstraZeneca Canada, Mississauga, ON], Suprefact [sanofi-aventis, Laval, QC], Eligard
[sanofi-aventis, Laval, QC], Trelstar [Watson Pharma Inc.
This is the second MAA MediGene has submitted for the Eligard
products -- in December of 2001 they submitted an MAA for the 7.
Table 19: Prostate Cancer, Global, Eligard
, Incidence of Adverse Effects, 2010 65
Table 21: Prostate Cancer, Global, Eligard
, Incidence of Adverse Effects, 2010 62
Medications in the GnRH class are marketed under the brand names Eligard
, Lupron, Synarel, Trelstar, Vantas, Viadur, and Zoladex.
45 (leuprolide acetate for injectable suspension), a 6-mo palliative hormone treatment for advanced prostate cancer.
sales in the second quarter were $67.